Serum proteomic profiling of dementia with Lewy bodies: diagnostic potential of SELDI-TOF MS analysis.
Dementia with Lewy bodies (DLB) is the second most common senile degenerative dementia after Alzheimer's disease (AD). The presentation of overlapping symptoms between these two disorders leads to difficulties in the determination of clinical entities. Serum samples were subjected to surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) analysis in order to identify a diagnostic marker for DLB. Four putative protein peaks (m/z 3,883, 4,964, 7,761 and 10,534) were differentially expressed in DLB patients compared to AD patients and control subjects. Receiver operating characteristics (ROC) analysis of a multivariate logistic model of the combination of three peaks (m/z 3,883, 7,761 and 10,534) exhibited the highest discriminatory ability of DLB subjects from non-DLB subjects with a sensitivity of 83.3%, a specificity of 95.8%, a positive predictive value of 90.9% and a negative predictive value of 92.0%. SELDI-TOF MS profiling, therefore, has revealed a serum signature with high diagnostic potential for DLB.
Wada-Isoe
K
K
Department of Neurology, Faculty of Medicine, Institute of Neurological Sciences, Tottori University, Yonago, Japan. kewada@grape.med.tottori-u.ac.jp
Michio
K
K
Imamura
K
K
Nakaso
K
K
Kusumi
M
M
Kowa
H
H
Nakashima
K
K
D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood*; D005260:Female; D006801:Humans; D020961:Lewy Body Disease / Q000097:blood* / Q000175:diagnosis*; D008297:Male; D040081:Protein Array Analysis; D040901:Proteomics / Q000379:methods*; D012372:ROC Curve; D012680:Sensitivity and Specificity; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
D015415:Biomarkers
Arthritis Rheum. 2005 Dec;52(12):3801-12
16320331
Ann Neurol. 2001 Sep;50(3):358-65
11558792
Clin Neurol Neurosurg. 2005 Aug;107(5):396-403
16023534
Neurobiol Aging. 2002 May-Jun;23(3):363-70
11959397
J Neurol Neurosurg Psychiatry. 2001 Nov;71(5):583-8
11606666
J Infect Dis. 2006 Nov 15;194(10):1356-66
17054064
Neurology. 2006 Apr 25;66(8):1218-22
16481598
Lancet Neurol. 2006 Mar;5(3):228-34
16488378
Lancet Neurol. 2004 Jan;3(1):19-28
14693108
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Apr 15;849(1-2):105-14
17097359
Proteomics. 2006 Dec;6(24):6405-15
17096316
Trends Pharmacol Sci. 2006 May;27(5):251-9
16600386
Neurosci Lett. 2004 Nov 3;370(1):36-9
15489013
Neurology. 1984 Jul;34(7):939-44
6610841
Arch Neurol. 2004 Jun;61(6):919-25
15210531
Neurology. 2005 Dec 27;65(12):1863-72
16237129